The production company Neostell SAS will be jointly created by Neovacs (70%) and Stellar Biotechnologies (30%) and it will be based in the Paris area.
The joint-venture agreement will combine the skills of the two companies in order to manufacture and sell all types of conjugated vaccines to third party customers worldwide, as well as produce all of Neovacsā Kinoids, including IFNĪ±-Kinoid. Investments for the new production unit will start after the results of the Phase 2b study of IFNĪ±-Kinoid in lupus conducted by Neovacs.